Clinical trials
CAR clinical trials
Below are recruiting car clinical trials, each written for real people, not researchers. We’re tracking 788 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT06827782Enrolling by invitationPhase 1
Cord blood CAR-NK cells for relapsed CNS lymphoma
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
Hangzhou, ZhejiangAges 18–75 - NCT03628612Enrolling by invitationPhase 2
Long-term follow-up after CAR T cell treatment
This study checks how people do over the long run after receiving a personalized, genetically modified CAR T cell treatment. It may help researchers understand long-term safety and outcomes, which can improve future care.
Miami, FloridaAges 1 year+ - NCT06514794RecruitingPhase 2
CAR-T cell therapy for T-cell leukemia and lymphoma
This trial tests a new CAR-T cell therapy (WU-CART-007) made from donor cells that target a protein called CD7 on cancer cells. It is for children and adults with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or is still present after treatment.
Duarte, CaliforniaAges 1 year+ - NCT06186401RecruitingPhase 1
Experimental immune cell therapy for a specific type of brain cancer
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT05486234Recruiting
Study to reduce cannabis and alcohol use with teen and caregiver
This study looks at ways to help teens cut down on cannabis and alcohol use. You may qualify if you’ve been using both in the last three months and your caregiver is able to join and consent.
Charleston, South CarolinaAges 13–17 - NCT06762431RecruitingPhase 1/Phase 2
CAR T-cell therapy plus lenalidomide for CLL
This trial tests a combination of two treatments—CAR T-cells (your own immune cells reprogrammed to attack cancer) and lenalidomide (a pill that boosts the immune system)—for people with chronic lymphocytic leukemia (CLL) that has not responded to or returned after at least one prior treatment. It aims to see if this combination is safe and works better than either alone.
Vitebsk, Select A StateAges 18 years+ - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT06630104Recruiting
Studying blood cell changes after CAR-T therapy for blood cancers
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
Scottsdale, ArizonaAges 18 years+ - NCT06236139RecruitingPhase 1/Phase 2
Immune cells plus hormone therapy for advanced prostate cancer
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
Seattle, WashingtonAges 18 years+ - NCT06940297RecruitingPhase 2
Dasatinib and quercetin with Carvykti for advanced multiple myeloma
This trial tests whether adding two drugs (dasatinib and quercetin) before CAR-T therapy (Carvykti) can improve outcomes for people with multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this combination is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT07665307Recruiting
Delayed side effects after CAR-T for multiple myeloma
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
San Francisco, CaliforniaAges 18 years+ - NCT07543055RecruitingPhase 1
CAR T-Cell Therapy for Advanced Prostate Cancer
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Hackensack, New JerseyAges 18 years+ - NCT07751380RecruitingPhase 1
CAR T-cell therapy for children and young adults with certain sarcomas
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
LondonAges 1–24 - NCT05809284Recruiting
Understanding CAR T-cell therapy persistence in young patients with ALL
This study looks at why CAR T-cell therapy stops working in some children and young adults with leukemia. It aims to help doctors understand how to make this treatment last longer.
LondonAges Up to 25 years - NCT06285825RecruitingPhase 2
Study of emapalumab for low blood counts after CAR T-cell therapy
This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.
Houston, TexasAges 18 years+ - NCT06575374RecruitingPhase 2
Letermovir to prevent CMV after CAR T-cell therapy
This trial tests if a drug called letermovir can safely prevent CMV (a common virus) from reactivating after you receive CAR T-cell therapy (Axi-cel). It may help reduce infections and side effects.
Houston, TexasAges 18 years+ - NCT06252402RecruitingEarly Phase 1
CAR T cells for HIV: A new immunotherapy study
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
Duarte, CaliforniaAges 18 years+ - NCT05437315RecruitingPhase 1/Phase 2
GD2/PSMA CAR-T therapy for hard-to-remove metastatic cancers
This early-phase study tests a custom immune-cell treatment (CAR-T) that targets two tumor markers called GD2 and PSMA. It may help people whose cancer is advanced, cannot be removed with surgery, and has the right marker pattern in their tumor tissue.
Shenzhen, GuangdongAges 1–75 - NCT05225363RecruitingPhase 1
CAR T therapy for ovarian cancer that no longer responds to platinum
This Phase 1 study tests a one-time treatment made from your immune cells (CAR T) to attack a protein found on some ovarian cancer cells. It is for people whose ovarian cancer has come back or worsened after platinum chemotherapy, aiming to see safety and early signs of benefit.
Duarte, CaliforniaAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT06788964RecruitingPhase 2
Bridge therapy with loncastuximab and rituximab before CAR-T for lymphoma
This trial tests a two-drug combination (loncastuximab tesirine and rituximab) as a short-term "bridge" treatment for people with large B-cell lymphoma who are waiting to receive standard CAR-T cell therapy. The goal is to control the lymphoma before the CAR-T cells can be given.
Salt Lake City, UtahAges 18 years+ - NCT06610344Recruiting
BHB supplement with CAR-T for lymphoma
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06271057RecruitingPhase 2
Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
CréteilAges 18 years+
Hear when a new CAR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car?
- Yes. Clin2 currently lists 788 recruiting car studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.